Bonadea

Quick links to important sections

Bonadea

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Bonadea

Quick Facts: What is Bonadea?

Bonadea is a prescription-only combination medication designed for systemic oral use. Its identity is defined by the balanced presence of two synthetic female hormones.

Property Description
Active Ingredients Dienogest (Progestin), Ethinyl Estradiol (Estrogen)
Form Film-Coated Tablet
Pharmacological Class Combined Hormonal Contraceptive (CHC)
Common Use Reversible contraception (pregnancy prevention)
Origin Synthetic hormones

What is Bonadea and How is it Classified?

Bonadea is a prescription-only medicinal product classified as a Combined Hormonal Contraceptive (CHC), presented as a film-coated tablet for oral administration. The drug is classified as a monophasic low-dose pill, which means it utilizes a consistent concentration of the active synthetic hormones across all active tablets.

This particular combination of Dienogest and Ethinyl Estradiol is a widely recognized formulation, also marketed under brands such as Jeanine and Sibilla Plus. The low-dose profile distinguishes it from older CHC formulations and is a strategy to maintain contraceptive efficacy while reducing the overall hormonal load.

The Active Components: Dienogest and Ethinyl Estradiol

The primary active ingredients in Bonadea are the synthetic progestin Dienogest and the synthetic estrogen Ethinyl Estradiol (EE). This dual composition provides the necessary hormonal entities to modulate the menstrual cycle. Dienogest is an orally-active progestin derived from 19-nortestosterone, which is primarily noted for its strong antiandrogenic properties.

This specific antiandrogenic action is a key identity feature of Bonadea, offering a therapeutic advantage for women with conditions like moderate acne alongside their need for reliable contraception.

Primary Purpose and General Action

The fundamental utility of Bonadea is to provide contraceptive efficacy, serving as a reliable and reversible method of contraception. This purpose is accomplished through a multi-faceted hormonal mechanism primarily focused on suppressing ovulation, preventing the release of an egg. Concurrently, the medicine causes the cervical mucus to thicken and modifies the uterine lining. These physical and environmental changes support the primary purpose and extend its general use for appropriate patient groups.

Regulatory References

  1. Monophasic Combined Oral Contraceptives

What side effects are possible with Bonadea?

Possible Side Effects and Safety Information: Bonadea

The safety profile of Bonadea (Dienogest/Ethinyl Estradiol) is characterized by both commonly reported reactions and rare, serious events associated with combined hormonal contraceptives (CHCs), as documented in official regulatory labeling.

Frequency-Classified Adverse Reactions

Adverse reactions are classified by official sources based on their documented incidence in clinical studies:

  • Very Common (Affecting ge 1 in 10 women): Headache.
  • Common (Affecting ge 1 in 100 to < 1 in 10 women): Nausea, vomiting, breast pain or discomfort, irregular uterine bleeding, and increased weight.

Other less frequent effects, classified as Uncommon, include migraine, dizziness, fluid retention, and changes in mood or libido.


Serious Adverse Reactions and Safety Constraints

The most significant risks are classified as Serious Adverse Reactions, primarily involving thromboembolic events. These include Venous Thromboembolism (VTE), such as Deep Vein Thrombosis and Pulmonary Embolism, and Arterial Thromboembolism (ATE), such as stroke and myocardial infarction. The official regulatory documents note that the risk of VTE is highest during the first year of use of any CHC.

Use of this medicine is subject to population-specific restrictions. It is contraindicated in women over 35 years of age who smoke and in those with certain pre-existing conditions, including severe hepatic disease or a history of specific vascular or thromboembolic disorders. Additionally, initiation is not recommended earlier than four weeks postpartum due to heightened thromboembolism risk in that period. The presence of these mandatory constraints defines the overall regulatory safety limitations for Bonadea.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documents regarding overdose with Bonadea (Dienogest/Ethinyl Estradiol) establish a specific profile focused on low acute toxicity and mandated symptomatic care.

Feature Official Regulatory Statement
Documented Manifestations Symptoms may include nausea, vomiting, and heavy withdrawal bleeding in women, along with breast tenderness and headache.
Severity Classification Acute overdose is generally classified as low toxicity and is not likely to be life-threatening. Serious adverse effects are not typically reported from isolated ingestion.
Population Notes Accidental ingestion by children typically results in minor, short-term symptoms only, although the potential risk of iron poisoning from non-hormonal placebo tablets must be excluded.

Emergency Response and Management

The regulatory guidance specifies required actions in the event of ingestion of multiple tablets:

  • Immediate medical attention is required for any suspected overdose to ensure clinical assessment.
  • Patients should contact emergency services or a Poison Control Center immediately for specific guidance and monitoring.
  • Treatment is symptomatic and supportive, as no specific antidote is known for the active hormonal ingredients.
  • Hospital observation may be required for monitoring of vital signs and management of any resulting symptoms.

The official overdose profile is defined by this low acute toxicity assessment, which dictates that the mandated response focuses on seeking immediate medical help for supportive management and clinical observation of the documented hormonal manifestations.

Therapeutic Uses of Bonadea

What Bonadea Treats: Main Uses and Benefits

Highly Reliable Contraception and Family Planning

The fundamental and primary therapeutic use of Bonadea is the highly reliable and reversible prevention of pregnancy. It is generally applied in the context of long-term family planning, and its consistent hormonal content supports long-term family planning for women of reproductive age.


Management of Androgen-Driven Acne and Menstrual Symptoms

This formulation is commonly used to treat moderate acne vulgaris and provides symptomatic support for pronounced menstrual disorders, including severe menstrual cramping (dysmenorrhea) and excessive menstrual blood loss (menorrhagia). The product is used for hormonal contraception and for the treatment of moderate acne in women who choose to use an oral contraceptive.

This use may assist with improvement in skin condition and contributes to a more predictable cycle, which assists with maintaining functional stability when symptoms interfere with routine activities.


Quick Fact: Symptom Clusters Managed
Symptom Domains: The medication is relevant for easing symptoms related to systemic imbalance, symptoms that interfere with daily functioning, and symptoms associated with episodic changes (like the menstrual cycle).

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Bonadea — Official Regulatory Information

The following information details the official population eligibility and non-eligibility rules for Bonadea, based strictly on governmental regulatory documents.

Classification Rule
Populations for whom use is allowed Females of reproductive potential (post-menarche) who require hormonal contraception, including those electing treatment for moderate acne.
Populations for whom use is not recommended Nursing mothers (due to potential impact on milk production) and women less than 4 weeks postpartum (due to elevated thromboembolism risk).
Populations for whom use is contraindicated Women with a history of or current thrombotic disorders (DVT, PE, stroke, ischemic heart disease), smoking and over age 35, severe liver disease or tumors, or known hormone-sensitive cancers (e.g., breast cancer).

Age/Condition Status Eligibility Status
Age-related eligibility rules Not indicated for use before menarche or for elderly women (postmenopausal).
Pregnancy eligibility status Contraindicated. Use must be discontinued immediately if pregnancy occurs.
Condition-specific restrictions Contraindicated in cases of uncontrolled hypertension, migraine with aura, undiagnosed abnormal uterine bleeding, and with specific Hepatitis C drug regimens.

Connection to the overall eligibility profile: Regulatory documents define eligibility primarily by absolute contraindications that exclude women with conditions significantly increasing the risk of blood clots and hormone-sensitive malignancies. Use is further restricted by age, prohibiting use before menarche and for elderly women, and by physiological status, strictly forbidding use during pregnancy.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Formal Regulatory Restrictions

The co-administration of Bonadea with specific Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, is formally contraindicated. This restriction is officially documented due to the risk of significant ALT (liver enzyme) elevations.


Pharmacokinetic Interactions

Most documented interactions are pharmacokinetic, involving drug metabolism. Strong CYP3A4 enzyme inducers, suchals Carbamazepine, Phenytoin, and Rifampicin, accelerate the clearance of the hormonal components through metabolic induction. This interaction officially leads to decreased contraceptive efficacy.


Exposure Modification and Timing Rules

Regulatory labeling requires using an alternative contraceptive method during the use of a strong inducer and for at least 28 days after discontinuation. Conversely, the Ethinyl Estradiol component acts as a CYP1A2 inhibitor, which can cause an increase in plasma concentrations of co-administered medicines, such as Melatonin.

Bonadea may also diminish the efficacy of Insulin and other antidiabetic agents due to a documented pharmacodynamic interference with blood glucose control. The herbal product St. John's wort and Grapefruit/Grapefruit Juice are officially restricted as they alter the systemic exposure of the medication. Hepatic impairment is noted as a condition that may alter drug exposure due to poor metabolism.

Mechanism of Action

Bonadea is a combination pharmaceutical comprising ethinylestradiol and dienogest, which exert their actions through molecular interactions with steroid hormone receptors, primarily within the hypothalamic-pituitary-ovarian (HPO) axis and target reproductive tissues.

Ethinylestradiol, an estrogen receptor agonist, provides negative feedback to the pituitary gland, suppressing the secretion of Follicle-Stimulating Hormone (FSH) and Luteinizing Hormone (LH). This suppression of gonadotropins inhibits ovarian follicular development and subsequent ovulation.

Dienogest functions as a progestin, acting as an agonist for the progesterone receptor. The progestational action further enhances the pituitary suppression of LH, contributing to an anovulatory state. Additionally, dienogest's action modifies the endometrium, inducing morphological and functional alterations. The combined systemic effect results in modulation of the HPO axis, leading to a state of suppressed ovarian cyclicity and an altered endometrial environment.

Dosage and Administration Information

How to Use Bonadea — Administration Guidelines

Bonadea, containing 2 mg dienogest and 0.03 mg ethinylestradiol, is an oral contraceptive administered on a precise, cyclic schedule.


Dosing Schedule and Route

Administration Detail Instruction
Route of Administration Oral use; the film-coated tablet must be swallowed whole.
Standard Daily Dose One active tablet (dienogest 2 mg / ethinylestradiol 0.03 mg) daily.
Cycle Duration A 28-day cycle consisting of 21 consecutive days of active tablets, followed by a 7-day tablet-free interval.

Administration Procedure and Timing

The tablet must be taken at approximately the same time every day to maintain consistent hormone levels. Tablets should be taken in the sequential order indicated on the blister pack to ensure the correct treatment cycle is followed.

For most users, including adolescents once menstruation has begun, no age-specific dose adjustment is necessary. The cycle must be strictly maintained: start the next pack after the 7-day tablet-free period, regardless of whether the withdrawal bleed has ended.

Instructions for Missed Doses

Specific guidance exists for managing missed doses:

  • If an active tablet is missed by less than 12 hours, take the tablet immediately, and continue taking subsequent tablets at the usual time. Contraceptive protection is maintained.
  • If an active tablet is missed by more than 12 hours, contraceptive protection may be reduced. Management depends on the specific week of the cycle the dose was missed in. Following the precise procedural steps for missed tablets is essential to minimize the risk of reduced effectiveness.

Recent Clinical Evidence

Research evidence / Overview of Studies for Bonadea

## Research Evidence for Pregnancy Prevention

The evidence base for the use of this combination pill for contraception has been built through large-scale clinical trials and long-term observational studies involving women of reproductive age. Research examined contraceptive reliability by monitoring and reporting the Pearl Index (PI), a standardized measure used to describe the occurrence of unintended pregnancies over time. These studies explored how consistent use of the combined hormones was observed in the research examining the primary outcome of pregnancy prevention.

Research also explored outcomes related to systemic or functional imbalance, such as cycle regularity and the patterns of withdrawal bleeding. Data show patterns related to pregnancy prevention that are consistent with research on the class of combined hormonal contraceptives.

## Research Evidence for the Treatment of Moderate Acne Vulgaris

The research exploring Bonadea for the treatment of moderate acne vulgaris has primarily used multicenter, randomized controlled trials (RCTs). These studies were conducted during periods of increased symptom activity in women who were also seeking oral contraception. Research examined outcomes linked to inflammatory or irritative states by measuring objective changes, such as the total number of acne lesions (both inflammatory and non-inflammatory) and using investigator-assessed global skin severity ratings.

Comparative trials described that the findings for acne were consistent with those reported for certain other combined hormonal anti-androgenic agents. A key limitation of the existing research is that the results apply only to the populations studied, which consist primarily of women with mild-to-moderate acne.

## Studies on Secondary Outcomes and Menstrual Support

Beyond the primary indications, this combination was studied for secondary patient-reported outcomes describing perceived discomfort associated with the menstrual cycle. Specifically, research monitored changes in the severity of dysmenorrhea (painful menstruation) and menorrhagia (heavy menstrual bleeding). Findings indicate patterns related to menstrual pain and blood loss was observed in some studies. However, these are typically tracked as secondary outcomes in trials primarily focused on contraception or acne; therefore, the evidence quality varies across studies when the specific endpoint is analyzed alone.

## Evidence in Specific Populations and Research Gaps

Overall, findings related to contraceptive use are broadly supported by years of use and multiple studies, but comparative evidence is lacking for certain endpoints, such as definitively comparing its menstrual symptom relief against all alternative CHCs. Official regulatory sources have noted that data are still emerging and are not fully established to accurately compare the risk of blood clots in veins (venous thromboembolism) with this specific combination against the risk associated with all other specific combined hormonal contraceptives.

Frequently Asked Questions (FAQ)

Common questions about Bonadea (FAQ)

Q: How does Bonadea make you feel better?

A: According to official regulatory documents, Bonadea works by regulating the body's natural hormone cycle, which stops ovulation and thickens cervical mucus for pregnancy prevention. Additionally, the progestin component has properties that block the effects of androgens (male hormones), which is associated with improving conditions like moderate acne vulgaris.

Q: How quickly should I expect Bonadea to start working?

A: The active components in Bonadea are quickly absorbed into the bloodstream after taking the tablet. However, the time it takes for the contraceptive effects to be established, or for noticeable improvements in conditions like acne to appear, is detailed in the official patient information, and the timeline depends on the day of the menstrual cycle the first tablet is taken.

Q: What happens if I miss a tablet-free period or start the next pack late?

A: If tablets are missed, especially during the third week of the cycle, specific procedures apply as outlined in the prescribing information. This may involve entirely omitting the tablet-free interval and starting a new pack immediately, which is necessary to maintain contraceptive protection. It is important to follow the precise procedural steps for managing the tablet-free interval, as outlined in the official prescribing information.

Q: What should I do if I accidentally take more Bonadea than usual?

A: Official regulatory documents indicate that taking a high number of tablets may cause certain mild side effects. These can include nausea, vomiting, or slight vaginal bleeding. Official overdose information notes that no serious harmful effects have been reported.

Q: Are there any foods I should completely avoid when on Bonadea?

A: The official regulatory documents restrict the use of grapefruit and grapefruit juice. This is because these products can alter how your body processes the medicine, potentially changing the overall exposure to the active ingredients.

Q: Can Bonadea be taken while breastfeeding (general question)?

A: The medicine is typically not recommended for use by nursing mothers. This is due to the potential that the active ingredients may be present in small amounts in breast milk, and because combined hormonal contraceptives may also affect milk production.

Q: Should people with a history of liver issues avoid Bonadea?

A: Official information states that Bonadea is contraindicated (must not be used) in the presence of severe hepatic disease (severe liver disease) or liver tumors. Any form of hepatic impairment can alter how the body metabolizes the medicine, potentially changing the level of exposure to the drug.

Q: Why do doctors often choose Bonadea over similar medications?

A: The decision to use Bonadea is based on clinical needs. Regulatory documents highlight that the progestin component, dienogest, has strong antiandrogenic properties. This provides a therapeutic advantage that is useful for women seeking reliable contraception who also require treatment for moderate acne vulgaris.

Q: What are the signs of a serious allergic reaction to Bonadea?

A: Official patient information generally advises immediately seeking medical help if signs of a severe allergic reaction occur. These rare but serious signs can include swelling of the face, tongue, or throat, or the sudden onset of difficulty breathing.

Q: Why is Bonadea sometimes prescribed for conditions other than its main use?

A: Bonadea is formally indicated for contraception and moderate acne vulgaris. However, studies have also tracked secondary effects related to menstrual support, such as relief from dysmenorrhea (painful menstruation) and menorrhagia (heavy menstrual bleeding). This additional evidence may be considered by a healthcare provider.

Q: Can Bonadea be crushed or split in half?

A: Official administration instructions specify that the film-coated tablet must be swallowed whole. Altering the tablet by crushing or splitting it is not addressed in the regulatory guidelines for administration.

Q: Does taking Bonadea mean I need to have regular blood tests?

A: Official safety documents recommend that while on combined hormonal contraceptives, you should have regular medical check-ups and follow-up examinations. These reviews typically involve a check of your risk factors and, where appropriate, may include laboratory testing.

Q: Are there any known interactions between Bonadea and common cold medications?

A: Interactions are commonly seen with medicines that affect the CYP450 enzyme system, such as strong CYP3A4 inducers. It is generally recommended to review the ingredients of common cold medicines to see if they contain any known interacting substances, as these can affect the hormone levels.

Q: What happens when you suddenly stop taking Bonadea?

A: When the medicine is discontinued, normal ovarian function usually returns. Regulatory safety information notes that the risk of venous thromboembolism (VTE), or blood clots, is highest shortly after starting or restarting use following a break of four weeks or more.

Q: When is the best time of day to take Bonadea?

A: The official prescribing information states that the tablet must be taken at approximately the same time every day to maintain consistent hormone levels. The time of day—morning versus evening—is not specifically designated, as long as the timing is consistent.

Q: Are there any known issues with Bonadea and pre-existing kidney problems?

A: Official regulatory documents do not indicate that a change in treatment is necessary for patients with existing kidney function disorders. However, patients should always inform their prescribing healthcare provider of this condition.

Q: How does Bonadea affect the uterine lining (endometrium)?

A: The progestin component of the medicine, dienogest, has a specific effect on the uterine lining, which is called the endometrium. This action induces changes to its morphology and function, which supports the medicine's overall contraceptive efficacy.

Q: Is Bonadea the same as [Name of common alternative drug]?

A: Bonadea contains the combination of dienogest and ethinyl estradiol. Official documents confirm that products containing this exact same hormonal combination are considered to be interchangeable. Other brands, such as Jeanine and Sibilla Plus, also use this formulation.

Q: How long does Bonadea stay in your system after you stop taking it?

A: Official pharmacokinetic studies indicate that the hormonal components, Ethinyl Estradiol and Dienogest, have a relatively short elimination half-life. They are generally cleared from the body within approximately 10 to 12 hours after the last dose is taken.

Q: Does Bonadea have any known effects on blood pressure?

A: The official product information notes that combined hormonal contraceptives may cause an increase in blood pressure. Official guidance emphasizes that blood pressure should be regularly monitored during treatment. Uncontrolled high blood pressure is a contraindication for its use.

Q: Is Bonadea considered a 'strong' medication?

A: Bonadea is officially classified as a monophasic low-dose combined hormonal contraceptive. This means it contains a consistent and relatively low concentration of the two active synthetic hormones across all of its active tablets.

How should Bonadea be stored and disposed of?

How to Store and Dispose of Bonadea

Bonadea tablets must be stored according to the official regulatory requirements for the combination product (Estradiol Valerate and Dienogest).

Storage Conditions

Requirement Specification
Temperature Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F)
Excursions Permitted between 15 C and 30 C (59 F and 86 F)

The medication is supplied in blister packs. It is a mandatory requirement that the product be kept out of reach of children.

Disposal Instructions

Official labeling does not contain product-specific instructions for disposal. Unused or expired Bonadea tablets should be disposed of in accordance with general guidelines provided by national health authorities, such as utilizing a drug take-back program or following instructions for discarding medicine in household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Bonadea found in:

A-Z Index: